Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

Autor: Schoenfeld JD; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Jonathan_Schoenfeld@dfci.harvard.edu., Giobbie-Hurder A; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Ranasinghe S; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kao KZ; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lako A; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tsuji J; Genomics Platform, Broad Institute, Cambridge, MA, USA., Liu Y; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Brennick RC; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gentzler RD; Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA., Lee C; Division of Hematology/Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Hubbard J; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA., Arnold SM; Division of Medical Oncology, University of Kentucky Markey Cancer Center, Lexington, KY, USA., Abbruzzese JL; Division of Medical Oncology, Duke Cancer Institute, Durham, NC, USA., Jabbour SK; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Uboha NV; Department of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine, Madison, WI, USA., Stephans KL; Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA., Johnson JM; Department of Medical Oncology, Sidney Kimmel Cancer Center-Jefferson Health, Philadelphia, PA, USA., Park H; Division of Oncology, Siteman Cancer Center, Washington University, Saint Louis, MO, USA., Villaruz LC; Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Sharon E; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Streicher H; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Ahmed MM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Lyon H; Genomics Platform, Broad Institute, Cambridge, MA, USA., Cibuskis C; Genomics Platform, Broad Institute, Cambridge, MA, USA., Lennon N; Genomics Platform, Broad Institute, Cambridge, MA, USA., Jhaveri A; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Yang L; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Altreuter J; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Gunasti L; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Weirather JL; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Mak RH; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Awad MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rodig SJ; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chen HX; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Monjazeb AM; Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA., Hodi FS; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2022 Feb; Vol. 23 (2), pp. 279-291. Date of Electronic Publication: 2022 Jan 13.

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.

Autor: Monjazeb AM; Department of Radiation Oncology, University of California Davis, Comprehensive Cancer Center, Sacramento, California., Giobbie-Hurder A; Dana-Farber Cancer Institute, Boston, Massachusetts., Lako A; Brigham and Women's Hospital, Boston, Massachusetts., Thrash EM; Dana-Farber Cancer Institute, Boston, Massachusetts., Brennick RC; Dana-Farber Cancer Institute, Boston, Massachusetts., Kao KZ; Dana-Farber Cancer Institute, Boston, Massachusetts., Manuszak C; Dana-Farber Cancer Institute, Boston, Massachusetts., Gentzler RD; University of Virginia, Charlottesville, Virginia., Tesfaye A; Karmanos Cancer Institute/Wayne State University, Detroit, Michigan., Jabbour SK; Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey., Alese OB; Winship Cancer Institute of Emory University, Atlanta, Georgia., Rahma OE; Dana-Farber Cancer Institute, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Cleary JM; Dana-Farber Cancer Institute, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Sharon E; Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland., Mamon HJ; Dana-Farber Cancer Institute, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Cho M; Department of Radiation Oncology, University of California Davis, Comprehensive Cancer Center, Sacramento, California., Streicher H; Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland., Chen HX; Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland., Ahmed MM; Radiation Research Program, NCI, Bethesda, Maryland., Mariño-Enríquez A; Dana-Farber Cancer Institute, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Kim-Schulze S; Mount Sinai School of Medicine, New York, New York., Gnjatic S; Mount Sinai School of Medicine, New York, New York., Maverakis E; Department of Dermatology, University of California Davis, School of Medicine, Sacramento, California., Marusina AI; Department of Dermatology, University of California Davis, School of Medicine, Sacramento, California., Merleev AA; Department of Dermatology, University of California Davis, School of Medicine, Sacramento, California., Severgnini M; Dana-Farber Cancer Institute, Boston, Massachusetts., Pfaff KL; Dana-Farber Cancer Institute, Boston, Massachusetts., Lindsay J; Dana-Farber Cancer Institute, Boston, Massachusetts., Weirather JL; Dana-Farber Cancer Institute, Boston, Massachusetts., Ranasinghe S; Dana-Farber Cancer Institute, Boston, Massachusetts., Spektor A; Dana-Farber Cancer Institute, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Rodig SJ; Dana-Farber Cancer Institute, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Hodi SF; Dana-Farber Cancer Institute, Boston, Massachusetts.; Brigham and Women's Hospital, Boston, Massachusetts., Schoenfeld JD; Dana-Farber Cancer Institute, Boston, Massachusetts. jdschoenfeld@partners.org.; Brigham and Women's Hospital, Boston, Massachusetts.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 May 01; Vol. 27 (9), pp. 2470-2480. Date of Electronic Publication: 2021 Feb 10.

Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade.

Autor: Zhou J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Li J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Guleria I; Tissue Typing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Chen T; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Giobbie-Hurder A; Center for Immuno-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Stevens J; Tissue Typing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Gupta M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Wu X; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Brennick RC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Manos MP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Center for Immuno-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. stephen_hodi@dfci.harvard.edu.; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. stephen_hodi@dfci.harvard.edu.; Center for Immuno-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. stephen_hodi@dfci.harvard.edu.; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. stephen_hodi@dfci.harvard.edu.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 Aug; Vol. 68 (8), pp. 1331-1340. Date of Electronic Publication: 2019 Jul 18.